Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines

Multiple Myeloma (MM)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

Blood Cancer J

Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B

doi: 10.1038/s41408-021-00408-4

Multiple Myeloma (MM)

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies

Int J Mol Sci.

Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S

doi: 10.3390/ijms19072087.

Multiple Myeloma (MM)

Efficacy and safety of elotuzumab for the treatment of multiple myeloma

Expert Opin Drug Saf.

Gavriatopoulou M, Terpos E, Kastritis E, Dimopoulos MA

doi: 10.1080/

Multiple Myeloma (MM)

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

JAMA Oncol.

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I

doi: 10.1001/jamaoncol.

Multiple Myeloma (MM)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde

Haematologica

Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, Van de Donk N, Terpos E, Broijl A, De Larrea CF, Gay F, Goldschmidt H, Hajek R, Vangsted AJ, Zamagni E, Zweegman S, Cavo M, Dimopoulos M, Einsele H, Ludwig H, Barosi G, Boccadoro M, Mateos MV, Sonneveld P, Miguel JS

doi: 10.3324/haematol.2021.278519

Multiple Myeloma (MM)

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

J Natl Compr Canc Netw.

Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R

doi: 10.6004/jnccn.2019.0049.

Multiple Myeloma (MM)

The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe

Expert Rev Hematol.

Cavo M, Terpos E, Bargay J, Einsele H, Cavet J, Greil R, de Wit E

doi: 10.1080/

Multiple Myeloma (MM)

Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma

Drugs.

Lamb YN

doi: 10.1007/s40265-018-0969-4.

Multiple Myeloma (MM)

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Leukemia.

Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H

doi: 10.1038/leu.2017.122.

Related content

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies

Efficacy and safety of elotuzumab for the treatment of multiple myeloma

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe

Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes